` ASTRAZEN (Astrazeneca Pharma India Ltd) vs BSE Sensex 30 Comparison - Alpha Spread

ASTRAZEN
vs
B
BSE Sensex 30

Over the past 12 months, ASTRAZEN has outperformed BSE Sensex 30, delivering a return of +19% compared to the BSE Sensex 30's +9% growth.

Stocks Performance
ASTRAZEN vs BSE Sensex 30

Loading
ASTRAZEN
BSE Sensex 30
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ASTRAZEN vs BSE Sensex 30

Loading
ASTRAZEN
BSE Sensex 30
Difference
www.alphaspread.com

Performance By Year
ASTRAZEN vs BSE Sensex 30

Loading
ASTRAZEN
BSE Sensex 30
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Astrazeneca Pharma India Ltd vs Peers

BSE Sensex 30
ASTRAZEN
LLY
JNJ
ROG
AZN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Astrazeneca Pharma India Ltd
Glance View

Market Cap
211B INR
Industry
Pharmaceuticals

AstraZeneca Pharma India Ltd., a pivotal name in the Indian pharmaceutical landscape, is an integral arm of the global biopharmaceutical titan, AstraZeneca PLC headquartered in Cambridge, UK. The company has woven itself into the fabric of healthcare by consistently delivering novel medicines designed to combat a range of illnesses that include oncology, cardiovascular, renal, and metabolic diseases, as well as respiratory ailments. In India, AstraZeneca Pharma has carved out a reputation for not only introducing cutting-edge research and development capabilities but also adapting its global innovations to fit the unique demands of the local market. By leveraging a robust pipeline of therapeutic solutions, the company plays a crucial role in the intersection of healthcare and technology, aiming to improve patient outcomes through personalized medicine and bioscience-led innovations. The business model of AstraZeneca Pharma India is anchored in its commitment to research-driven innovation and strategic partnerships. Revenue streams are tightly interlinked with the company’s ability to successfully commercialize its extensive portfolio of patented medicines. AstraZeneca focuses on maintaining strong relationships with healthcare professionals and stakeholders, which are pivotal in driving prescriptions and ensuring the adoption of its novel therapies. Sales and distribution channels are fortified through collaborations with hospitals, pharmacies, and other healthcare providers, ensuring a broad reach across the country. The company continues to invest in its capabilities to educate and train medical professionals, thus enhancing its influence in the medical community and reinforcing its position as a market leader in providing life-saving medications.

ASTRAZEN Intrinsic Value
2 624.14 INR
Overvaluation 69%
Intrinsic Value
Price
Back to Top